PASG logo

PASSAGE BIO INC

PASGNASDAQ
πŸ† #4692 by market capEarnings Mar 2US Equity
$3.92β–² $0.31 (+8.59%)
Market closed Β· at close
πŸ””
Track PASG
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 8.6%
7dβ–Ό 7.1%
14dβ–² 4.7%
30dβ–² 7.8%
ytdβ–Ό 66.4%
1yβ–Ό 48.8%
🏦Market Cap
$13M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$3.51 – $3.94
52-Week Range
$3.29 – $20.00
Volume (shares)
27,965
Avg Volume (shares)
β€”
Shares Outstanding
3.2M
Next Earnings
2027-03-02

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-11.32
Dividend Yield
β€”
Dilution (1yr)
+2.2%
PASG logo

PASSAGE BIO INC

PASG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$43Mβ–Ό βˆ’38.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$32Mβ–Ό βˆ’34.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.2Mβ–² +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$22Mβ–² +$10M YoY
StockOtter Β· stockotter.space

About PASSAGE BIO INC

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy4
Hold3
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

Globe News WireΒ·27d ago

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger β€” BWMN, UTZ , PASG and FNWD

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a

GuruFocusΒ·27d ago

MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD

MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWDPR NewswireNEW YORK, Oct. 25, 2026NEW YORK, Oct. 25, 20

GuruFocusΒ·Oct 21

PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the

GlobeNewsWireΒ·Oct 20

$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger β€” UTZ, SAFT, PASG and FNWD

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the β€œM&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a T

Defense WorldΒ·Oct 16

Passage Bio, Inc. (NASDAQ:PASG) Stock Has Average Price Target of $13.25 According to Brokerages

Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have earned a consensus rating of "Hold" from the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the st

Defense WorldΒ·Oct 11

Passage Bio (NASDAQ:PASG) Stock Falls 2.4% – Here’s What Happened

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) shares traded down 2.4% during mid-day trading on Friday. The stock traded as low as $3.61 and last traded at $3.69. Approximately 12,111 shares were traded during tradi